Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew H Collins

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Trials|October 9, 2020
The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, MexicoPablo Manrique-Saide, Natalie E Dean, M Elizabeth Halloran, et al.
The Journal of Infectious Diseases|February 9, 2022
Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model InoculumNadine Rouphael, Allison Beck, Amy E Kirby, et al.
Science Immunology|June 13, 2020
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Journal of Clinical Microbiology|October 17, 2020
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in SalivaNora Pisanic, Pranay R Randad, Kate Kruczynski, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Frontiers in Public Health|December 10, 2021
Application of SARS-CoV-2 Serology to Address Public Health PrioritiesAmy C Sherman, Teresa Smith, Yerun Zhu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 11, 2018
Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8<sup>+</sup> T CellsAlba Grifoni, Priscilla Costa-Ramos, John Pham, et al.
The Lancet. Global Health|June 14, 2024
Neurodevelopment in preschool children exposed and unexposed to Zika virus in utero in Nicaragua: a prospective cohort studyRyan Max, Christian Toval-Ruiz, Sylvia Becker-Dreps, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
The American Journal of Tropical Medicine and Hygiene|May 1, 2026
Integrated Surveillance Strategies and Clinical Characteristics of Arboviral Diseases in a Pediatric Cohort in Merida, Mexico, 2021-2023Gloria A Barrera-Fuentes, Chiara Antonioli, Norma Pavia-Ruz, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Trials|October 9, 2020
The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, MexicoPablo Manrique-Saide, Natalie E Dean, M Elizabeth Halloran, et al.
The Journal of Infectious Diseases|February 9, 2022
Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model InoculumNadine Rouphael, Allison Beck, Amy E Kirby, et al.
Science Immunology|June 13, 2020
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Journal of Clinical Microbiology|October 17, 2020
COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in SalivaNora Pisanic, Pranay R Randad, Kate Kruczynski, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus AntibodiesLakshmanane Premkumar, Bruno Segovia-Chumbez, Ramesh Jadi, et al.
Frontiers in Public Health|December 10, 2021
Application of SARS-CoV-2 Serology to Address Public Health PrioritiesAmy C Sherman, Teresa Smith, Yerun Zhu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 11, 2018
Cutting Edge: Transcriptional Profiling Reveals Multifunctional and Cytotoxic Antiviral Responses of Zika Virus-Specific CD8<sup>+</sup> T CellsAlba Grifoni, Priscilla Costa-Ramos, John Pham, et al.
The Lancet. Global Health|June 14, 2024
Neurodevelopment in preschool children exposed and unexposed to Zika virus in utero in Nicaragua: a prospective cohort studyRyan Max, Christian Toval-Ruiz, Sylvia Becker-Dreps, et al.
The Lancet. Infectious Diseases|May 14, 2022
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trialEmily E Coates, Srilatha Edupuganti, Grace L Chen, et al.
The American Journal of Tropical Medicine and Hygiene|May 1, 2026
Integrated Surveillance Strategies and Clinical Characteristics of Arboviral Diseases in a Pediatric Cohort in Merida, Mexico, 2021-2023Gloria A Barrera-Fuentes, Chiara Antonioli, Norma Pavia-Ruz, et al.
Pageof 7